DCPH News and Press, Deciphera Pharmaceuticals Inc. From 08/04/20

- QINLOCK TM Approved for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor and U.S. Commercial Launch Underway - - Reported QINLOCK Net Revenue of $4.8 Million in the First Partial Quarter of Launch - - Company Expects to Complete Enrollment in Phase 3 INTRIGUE Study ...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on...

China NMPA acceptance of NDA follows recent U.S. FDA approval for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib SHANGHAI, China and SAN FRANCISCO and WALTHAM, Mass., July 20, 2020 (GLOBE NEWSWI...

The Australian Therapeutic Goods Administration has approved Deciphera Pharmaceuticals' (NASDAQ: DCPH ) QINLOCK (ripretinib), a switch-control tyrosine kinase inhibitor, for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatm...

- QINLOCK is the First Approved Tyrosine Kinase Inhibitor Designed Specifically for GIST Regardless of Patients’ Mutational Status - - QINLOCK Approved via the U.S. FDA’s Project Orbis Initiative - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that th...

-  Clinically Meaningful Benefit Observed in Patients Receiving QINLOCK Following Progression on Placebo - - Data Featured at the ESMO World Congress on Gastrointestinal Cancer 2020 Virtual Meeting - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentati...

- QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in Global INVICTUS Phase 3 Study - - QINLOCK Approved via the U.S. FDA’s Project Orbis Initiative - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced tha...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Tucker Kelly, Executive Vice President, Chief Financial Officer and Treasurer, will present at the JMP Securities Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:40 PM ET. The conference will be held in a virtual...

- QINLOCK Approved May 15 th by the U.S. FDA for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor - - Published Study Findings Detail the Activity of QINLOCK, a Switch-Control Tyrosine Kinase Inhibitor, Against a Broad Spectrum of KIT and PDGFRα Mutations - Deci...

In the last decade alone, scientists have made notable progress understanding cancer progression and developing targeted treatments that significantly improve outcomes. One of the best examples is gastrointestinal stromal tumors (GIST).  As recently as the late 1990s, doctors knew relative...